- Therapeutic compounds
-
The present invention provides compounds of formula (I): wherein: R1, R2, R3 R4, R5, R6, X, - - - , m, and n have any of the values defined in the specification, as well as pharmaceutical compositions comprising the compounds or salts thereof. The inventi
- -
-
-
- Benzisoxazoles and phenones as α2-antagonists
-
The present invention concerns compounds of formula (I) the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein Alk is C5-12alkanediyl; n is 1 or 2; p is 1 and q is 2; or p is 2 and q is 1; X is —O—, —S—, —S(═O)—, —S(═O)2— or NR2; each R1is independently hydrogen, halogen, C1-6alkyl, nitro, hydroxy or C1-4alkyloxy; R2is hydrogen, C1-6alkyl, aryl or C1-6alkyl substituted with aryl; aryl is phenyl or phenyl substituted with a halogen or C1-6alkyl; D is an optionally substituted benzophenone or 3-benzisoxazolyl; having central α2-adrenoceptor antagonist activity. It further relates to their preparation, pharmaceutical use and compositions.
- -
-
-
- Tricylic delta 3-piperidines as pharmaceuticals
-
The present invention concerns the compounds of formula the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein Alk is C1-6alkanediyl; n is 1 or 2; X is —O—, —S—, —S(═O)— or —S(
- -
-
Page column 13
(2010/02/05)
-
- 1,2,3,4-tetrahydro-benzofuro[3,2-C]pyridine derivatives
-
PCT No. PCT/EP98/02136 Sec. 371 Date Oct. 4, 1999 Sec. 102(e) Date Oct. 4, 1999 PCT Filed Apr. 2, 1998 PCT Pub. No. WO98/45297 PCT Pub. Date Oct. 15, 1998The present invention concerns the compounds of formula the N-oxides, the pharmaceutically acceptable
- -
-
-